{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:45:20Z","timestamp":1774266320829,"version":"3.50.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,5]]},"abstract":"<jats:p>\n                    Antiretroviral regimens for human immunodeficiency virus (HIV) infection have continuously evolved; however, antiretrovirals can cause severe adverse reactions. Two-drug regimen therapy can decrease lifetime cumulative drug exposure and long-term toxicities associated with multiple antiretrovirals. The preferred 2-drug regimen constitutes dolutegravir (DTG) and lamivudine (3TC). This study determined the rate of virological suppression and incidence of adverse events at week 48 in treatment-na\u00efve people living with HIV initiated on DTG\u2005+\u20053TC. This was a single-center, retrospective, observational study. Treatment-na\u00efve people aged \u226518 years who received at least 1 DTG\u2005+\u20053TC dose between May 2020 and May 2022 were included. Eighty-nine people living with HIV were enrolled. Twenty-five (28.1%) patients with a DTG\u2005+\u20053TC regimen at baseline were analyzed because of comorbidities, and 48% because of concomitant tuberculosis (TB). Viral suppression at 48 weeks was achieved in 91.67% of patients, and TB was well controlled. At week 48, 84 (94.38%) patients had viral loads\u2005&lt;\u200550 copies\/mL, and 21 (91.31%) of the 23 participants with a baseline HIV-1-RNA level\u2005\u2265\u20051\u2005\u00d7\u200510\n                    <jats:sup>5<\/jats:sup>\n                    copies\/mL achieved virological success. Fifteen (88.23%) of the 17 participants with a baseline CD4\u2005+\u2005cell count of &lt;200 cells\/\u00b5L achieved virological suppression. The median CD4\u2005+\u2005cell count change from baseline was 539.5 cells\/\u00b5L. No significant changes in triglycerides, low-density lipoprotein cholesterol, weight, or creatinine were observed from baseline to 48 weeks. One patient had severe insomnia at 4 weeks. Our findings support the real-world effectiveness and low metabolic impact of DTG\u2005+\u20053TC. Using DTG\u2005+\u20053TC in patients coinfected with TB and HIV has favorable therapeutic outcomes.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000038558","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T16:01:40Z","timestamp":1720195300000},"page":"e38558","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and safety of dolutegravir plus lamivudine in treating HIV in China, including outcomes of patients coinfected with tuberculosis"],"prefix":"10.1097","volume":"103","author":[{"given":"Haohua","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Xi\u2019an Eighth\u2019s Hospital, Xi\u2019an, Shaanxi, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanhuan","family":"Ba","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Xi\u2019an Eighth\u2019s Hospital, Xi\u2019an, Shaanxi, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Xi\u2019an Eighth\u2019s Hospital, Xi\u2019an, Shaanxi, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Xi\u2019an Eighth\u2019s Hospital, Xi\u2019an, Shaanxi, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Xi\u2019an Eighth\u2019s Hospital, Xi\u2019an, Shaanxi, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Xi\u2019an Eighth\u2019s Hospital, Xi\u2019an, Shaanxi, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8441-9879","authenticated-orcid":false,"given":"Juan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Xi\u2019an Eighth\u2019s Hospital, Xi\u2019an, Shaanxi, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.","volume":"4","year":"2017","journal-title":"Lancet HIV"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5582\/bst.2018.01309","article-title":"A Clinical scoring model to predict mortality in HIV\/TB co-infected patients at end stage of AIDS in China: an observational cohort study.","volume":"13","author":"Zhang","year":"2019","journal-title":"Biosci Trends"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2019.09.002","article-title":"Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.","volume":"54","author":"Baldin","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dky467","article-title":"Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).","volume":"74","author":"Joly","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jac\/dkad102","article-title":"Effectiveness and tolerability of dolutegravir\/lamivudine for the treatment of HIV-1 infection in clinical practice.","volume":"78","author":"Su\u00e1rez-Garc\u00eda","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 Recommendations of the International Antiviral Society-USA Panel.","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"R7-20260109","first-page":"1182","article-title":"\u4e2d\u56fd\u827e\u6ecb\u75c5\u8bca\u7597\u6307\u5357 (2021\u5e74\u7248).","volume":"27","year":"2021","journal-title":"%J \u4e2d\u56fd\u827e\u6ecb\u75c5\u6027\u75c5"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel.","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"21678","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.","volume":"20","author":"Cahn","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/jac\/dky564","article-title":"Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies\/mL: week 48 outcomes from ACTG 5353.","volume":"74","author":"Nyaku","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/14787210.2022.2128766","article-title":"Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China.","volume":"20","author":"Yang","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.21037\/jlpm.2018.01.10","article-title":"CD4:CD8 ratio and CD8+ cell count for prognosticating mortality in HIV-infected patients on antiretroviral therapy.","volume":"3","author":"Jenks","year":"2018","journal-title":"J Lab Precis Med"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/0956462419834129","article-title":"CD4\/CD8 ratio improvement in HIV-1-infected patients receiving dual antiretroviral treatment.","volume":"30","author":"Monsalvo","year":"2019","journal-title":"Int J STD AIDS"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1007\/s12325-021-01842-3","article-title":"Safety and effectiveness analysis of Dolutegravir in patients with HIV-1: interim report of post-marketing surveillance in Japan.","volume":"38","author":"Hongo","year":"2021","journal-title":"Adv Ther"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2125.2012.04440.x","article-title":"A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.","volume":"75","author":"Koteff","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3390\/genes14061214","article-title":"Genetic determinants of atherogenic indexes.","volume":"14","author":"Texis","year":"2023","journal-title":"Genes (Basel)"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijcard.2017.12.069","article-title":"Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a Nationally Representative Survey of 163,641 adults.","volume":"260","author":"Zhang","year":"2018","journal-title":"Int J Cardiol"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"e2201","DOI":"10.1097\/MD.0000000000002201","article-title":"Prevalence of dyslipidemia among antiretroviral-naive HIV-infected individuals in China.","volume":"94","author":"Shen","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1093\/jac\/dkz217","article-title":"Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting.","volume":"74","author":"Barcelo","year":"2019","journal-title":"J Antimicrob Chemother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:04:05Z","timestamp":1767967445000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":20,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038558","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]}}}